The story follows the life and survival of conjoined twin sisters. The book also won The Booksellers 2016 prize for young adult fiction and the Irish Childrens Book of the Year. In Lilo & Stitch: The Series, Swapper are Ischiopagus twin green stubby limbed lizard-like experiment with black eyes, purple markings on his back and three purple-tipped tendrils on each head that can emit a green ray from each heads eyes. The ray will swap the minds and voices of the targets,  and the only means of returning to normal is through Swapper choosing to do so. Because Swapper is two heads on the same body, Swapper is two beings cooperating as one, though their personalities mirror each other: they can be indecisive at times but usually work well together. In Big-Top Pee-wee, the Cabrini Circus has some conjoined twins named Ruth and Dot (portrayed by Helen Infield Siff and Carol Infield Sender). In The Addams Family and Addams Family Values, there are conjoined twins named Flora and Fauna Amor (portrayed by Darlene and Maureen Sue Levin) who were once dates to Gomez Addams and Uncle Fester. Both films also featured a two-headed relative named Dexter and Donald Addams (portrayed by Douglas Brian Martin and Steven M. Martin). In The Addams Family cartoon in 1992, the episode "N.J. Addams" featured Aunt Noggin who was a two-headed person who wears a Victorian dress. One head is black and speaks in a Jamaican accent and the other head is Caucasian and speaks in a Brooklyn accent.
The results showed that 67.2% of peanut (Arachis hypogaea) allergen powder recipients tolerated a 600 mg dose of peanut protein in the challenge, compared to 4.0% of placebo recipients.The safety of peanut (Arachis hypogaea) allergen powder was assessed in two double-blind, placebo-controlled studies in approximately 700 peanut-allergic individuals.On 21 December 2018, Aimmune Therapeutics applied Biologics License Application for Peanut (Arachis hypogaea) Allergen Powder-dnfp to the U.S. Food and Drug Administration. On 13 September 2019, the FDA Allergenic Products Advisory Committee decided seven to two in favour of the approval. The final approval was issued on 31 January 2020.On 15 October 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Palforzia, intended for desensitizing children and adolescents to peanut allergy. It was approved for medical use in the European Union in December 2020. Controversy
Although the FDA had decided the approval of Palforzia in 2019,  the Institute for Clinical and Economic Review (ICER) reported that the clinical evidence is still insufficient. A 2019 systematic review and meta-analysis of 12 clinical trials consisting of 1041 cases questioned the safety of oral peanut allergen treatment. The study concluded that the treatments "increase allergic and anaphylactic reactions over avoidance or placebo, despite effectively inducing desensitisation." References
Further reading
The PALISADE Group of Clinical Investigators (November 2018). "AR101 Oral Immunotherapy for Peanut Allergy". New England Journal of Medicine. 379 (21): 1991–2001. doi:10.1056/nejmoa1812856. ISSN 0028-4793. PMID 30449234.